Blueprint Medicines
Rigel Pharma Acquires US Rights to Blueprint Medicines' Gavreto
Blueprint regained rights to Gavreto this year after Roche ended its collaboration agreement for the drug.
Roche, Blueprint Medicines Withdraw Gavreto in RET-Mutant Medullary Thyroid Cancer in US
Genentech has decided it will no longer pursue the confirmatory trial for Gavreto in this setting due to feasibility.
The Association of Community Cancer Centers is on a mission to show the value of this new role in helping patients navigate institutional, technical, and financial barriers to testing.
Roche to Terminate Gavreto Deal With Blueprint Medicines
Blueprint will regain global commercialization rights for the RET inhibitor following Roche's decision to end the collaboration for strategic reasons.
FDA Places Partial Clinical Hold on Phase I Trial of Blueprint's CDK2 Inhibitor
The company will not enroll any new patients in the VELA trial while it investigates incidents of visual adverse events in some patients who received BLU-222.